Medicare may begin to cover renal denervation with Medtronic’s Symplicity device by October, which could drive coverage among ...

Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price target of ...

Medtronic says CMS is opening a national coverage analysis on renal denervation (RDN) procedures for patients with ...

Medtronic Vietnam and the University Medical Center Ho Chi Minh City (UMC HCMC) have signed their fourth Memorandum of ...

Medtronic (NYSE: MDT) announced today that it received CE mark approval for its BrainSense adaptive deep brain stimulation ...

Medtronic said the Centers for Medicare & Medicaid Services is opening a coverage analysis on renal denervation for patients with hypertension that will include the review of its medical device. The ...

Overall, Medtronic's dividend is safe for now, but there may be better income-generating investments out there to choose from ...

Medtronic is picking up steam with recent product launches, and its balance sheet is a fortress. Read more about MDT stock ...

J.P. Morgan analysts said the CMS’ review “validates the technology and could potentially move the needle on growth for Medtronic.” ...

While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now ...

TD Cowen analyst Josh Jennings maintained a Buy rating on Medtronic (MDT – Research Report) today and set a price target of $95.00. The ...

Medtronic offers solid income potential with a 3.5% dividend yield. Read why MDT stock’s forward P/E ratio signals possible ...